Article Figures & Tables
Figures
- Figure 1:
Intention-to-treat distribution of palivizumab doses administered to young children with congenital heart disease in British Columbia, November 2012 to April 2016.
- Figure 2:
Hospital admissions for lower respiratory tract infection (LRTI), November 2012 to April 2016. Data are reported as number of children-approvals (i.e., approvals for each season in children who received palivizumab for more than 1 season are counted separately). Note: RSV = respiratory syncytial virus.
Tables
- Table 1:
Clinical characteristics of 325 children with congenital heart disease enrolled in the British Columbia RSV Immunoprophylaxis Program
Characteristic % (95% CI)* Gestational age, wk, mean ± SD (n = 318) 36.9 ± 6.2 Birth weight, g, mean ± SD (n = 319) 2870 ± 871 Male sex (n = 324) 52 (46–57) Age at start of first season, mo, median (IQR) 2.2 (0–6.0) Surgical correction† (n = 315) 51 (45–57) Required bypass procedure (n = 288) 34 (29–40) Died 4.0 (2.1–6.7) - Table 2:
Clinical characteristics of infants with RSV-confirmed lower respiratory tract infection versus those whose admissions for lower respiratory tract infection were RSV-negative
Characteristic RSV-confirmed
n = 17RSV-negative
n = 40Gestational age, wk, mean ± SD 37.7 ± 2.5 37.8 ± 2.3 Birth weight, g, mean ± SD 2939 ± 748 2778 ± 651 Male sex, % (95% CI) 47 (23–72) 50 (34–66) Age at first in-season hospital admission, mo, median (IQR) 5 (4–10) 6 (4–13) Type of congenital heart disease,* % (95% CI) Cyanotic 47 (23–72) 50 (34–66) Left–right shunt 35 (14–62) 33 (19–49) Obstructive lesion 12 (1.5–36) 5 (0.6–17) Cardiomyopathy 6 (0.0–29) 2 (0.0–13) Combination 0 10 (2.8–24) Surgical correction, % (95% CI) 47 (23–72) 48 (32–64)† Required bypass procedure, % (95% CI) 25 (7.3–52)‡ 40 (24–58)§ Died, % (95% CI) 12 (1.5–36) 7 (1.5–20)
In this issue
Article tools
Related Articles
Cited By...
- No citing articles found.